Business
OWC Pharmaceutical Research Corporation to Present at the 2018 Wall St Conference
OWC Pharmaceutical Research Corporation to Present at the 2018 Wall St Conference.
About this update from Owc Pharmaceutical Research Corp
[{"type":"text","content":"\n\n\n\nOWC Pharmaceutical Research Corporation to Present at the 2018 Wall St Conference\n\n\n\n\n\nOWC Pharmaceutical Research Corporation to Present at the 2018 Wall St Conference\nPR Newswire\nPETACH TIKVA, Israel, January 8, 2018\n\n\n\nPETACH TIKVA, Israel, January 8, 2018 /PRNewswire/ --\n\nOWC Pharmaceutical Research Corp. [OWC Pharma](OTCQB: OWCP) is pleased to announce it will be a Diamond Sponsor at the 2018 Wall Street Conference. (http://WallStConference.com )\n\n     (Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg )\n\n\nThis is second consecutive year OWC Pharma will be attending this prestigious investment conference to be held on February 21st , 2018 at the Hilton Doubletree Hotel & Convention Center in Boca Raton, Florida.\n\nThe Wall Street Conference is one of the premiere conferences in the venture capital arena and Small Cap marketplace. Financial industry leaders from the hedge fund, investment banking, and private equity worlds, as well as sophisticated investors, attend the Wall Street Conference every year to discuss significant trends in emerging and growth industries.\n\nDr. Stanley Hirsch OWC Pharma Chairman commented, \"I am delighted to be attending and presenting at the 2018 Wall Street   Conference. I look forward to updating our supporters on current developments within the expanding medical cannabis industry in general and specifically within our company.\"\n\n\"It is an honor to have OWC Pharma participating again at the 2018 Wall Street Conference as a Diamond sponsor. They have a world class management team and are at the cutting edge of Medical Cannabis Research,\" said Jason Lyons, Founder and CEO of the Wall Street Conference.\n\nAbout OWC Pharmaceutical Research Corp. \n\nOWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively \"OWC\" or the \"Company\") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators....